{"id":"W3185045240","doi":"10.1007/s41669-021-00286-3","title":"Economic Model to Evaluate the Cost-Effectiveness of Second-Line Nilotinib Versus Dasatinib for the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (CML-CP) in Italy","year":2021,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Nilotinib; Dasatinib; Medicine; Imatinib; Internal medicine; Tyrosine-kinase inhibitor; Myeloid leukemia; Tyrosine kinase; Cost effectiveness; Oncology; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002198345,0.001908861,0.001588356,0.001262678,0.0004184465,0.001809795,0.002011652,0.002090303,0.008063327],"category_scores_gemma":[0.004777253,0.0007504546,0.001981698,0.00119782,0.0007284269,0.0009374102,0.001013194,0.001638505,0.0004988565],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00592882,"about_ca_system_score_gemma":0.003984787,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.02419754,"about_ca_topic_score_gemma":0.01052056,"domain_scores_codex":[0.9988375,0.0007600428,0.00002837617,0.0001066589,0.00007744186,0.0001900833],"domain_scores_gemma":[0.9979857,0.00151544,0.0001999409,0.00003232102,0.0001350233,0.0001315064],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","study_design_scores_codex":[0.0004034507,0.00006793598,0.001564811,0.00008620077,0.0001392345,0.0001392282,0.00001437509,0.9919739,0.0001051932,0.003123135,0.0005963294,0.001786086],"study_design_scores_gemma":[0.0003908251,0.0003573976,0.001625398,0.00005582389,0.0002145367,0.0001240086,0.00004984541,0.9936305,0.00008443702,0.002192898,0.001257107,0.0000171562],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.794802,0.006064818,0.1112595,0.006071809,0.0003661371,0.001845961,0.0143018,0.0003075451,0.06498038],"genre_scores_gemma":[0.9802239,0.001049592,0.008394547,0.00031561,0.00004459352,0.0007293962,0.002146047,0.00002783011,0.007068442],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02419754,"threshold_uncertainty_score":0.04811341,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1007693090773644,"score_gpt":0.4117837647717765,"score_spread":0.3110144556944122,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}